TABLE 4.
Dose, duration, and adherence analysis for primary and secondary outcomes for IBD overall
| Statin usage | n(%) | Steroid use
|
Anti-TNF
|
Abdominal surgery
|
Hospitalization
|
Composite outcome
|
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | ||
| Dose* | ||||||
| Unexposed | 9,871 (83.3) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Low dose | 1,334 (11.3) | 0.86 (0.73, 1.01) | 0.55 (0.31, 0.99) | 0.80 (0.60, 1.06) | 0.86 (0.70, 1.06) | 0.87 (0.76, 0.99) |
| High dose | 652 (5.5) | 0.72 (0.56, 0.93) | 1.08 (0.58, 1.98) | 0.80 (0.54, 1.20) | 0.92 (0.69, 1.21) | 0.90 (0.74, 1.09) |
| Duration | ||||||
| Unexposed | 9,871 (83.3) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| ≤90 days | 644 (5.4) | 0.84 (0.62, 1.14) | 1.16 (0.42, 3.20) | 0.84 (0.41, 1.70) | 0.93 (0.59, 1.47) | 0.92 (0.70, 1.20) |
| >90 days | 1,342 (11.3) | 0.81 (0.70, 0.95) | 0.67 (0.41, 1.07) | 0.80 (0.62, 1.02) | 0.87 (0.73, 1.05) | 0.87 (0.77, 0.98) |
| Adherence | ||||||
| Unexposed | 9,871 (83.3) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| MPR ≥0.80 | 1,472 (12.4) | 0.88 (0.75, 1.02) | 0.71 (0.43, 1.15) | 0.80 (0.61, 1.04) | 0.84 (0.69, 1.02) | 0.89 (0.79, 1.01) |
| MPR ≥0.90 | 1,220 (10.3) | 0.82 (0.69, 0.98) | 0.68 (0.39, 1.17) | 0.73 (0.54, 0.99) | 0.71 (0.57, 0.89) | 0.80 (0.69, 0.93) |
HRs were determined via Cox proportional hazard models, adjusting for potential confounders including including geographic region, Charlson comorbidity index, a diagnosis of coronary artery disease, weight loss or anemia, pre-exposure use of aminosalicylates, 6MP or azathioprine, rectal steroids, outpatient contacts and hospitalizations prior to exposure. The adjustment set differed slightly for each outcome.
*
High and low dose based on mean and median dose for each statin type.
HR: Hazard ratio; MPR: medication possession ratio